Informing infection

Inflammatix Inc. measures gene expression patterns in host cells to diagnose and inform treatment decisions for acute infections and sepsis faster than marketed tests. By following the host response, not the pathogen, the company can distinguish bacterial from viral infections and determine the risk of sepsis.

CEO Tim Sweeney told BioCentury Inflammatix is targeting the rapid PCR-based diagnostic for point-of-care use, based on its ability to measure the immune response in under an hour. He noted that most marketed tests take multiple days to read out, leading physicians to select a treatment based on clinical symptoms rather than the nature of an infection. ...